Decoy Therapeutics vs NanoViricides
DCOY and NNVC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DCOY and NNVC compare
NanoViricides is the larger company, worth 49 times as much as Decoy Therapeutics ($31.4M against $639K).
Decoy Therapeutics scores higher on the StockData Score (6 against 5 for NanoViricides), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DCOY | NNVC |
|---|---|---|
| Size and price | ||
| Market cap | $639K | $31.4M |
| Share price | $0.975 | $1.23 |
| Change, 1 year | −92.9% | −18.0% |
| Change, 5 years | −100.0% | −73.2% |
| Beta (5Y) | 0.77 | 0.77 |
| Employees | 11 | 7 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.1× (better) | 3.6× |
| FCF yield | – | −24.8% |
| Profitability | ||
| Return on equity | −11103% | −101% (better) |
| Return on invested capital | – | −111% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.97 | 2.66 (better) |
| Altman Z-score | −21.96 | −9.11 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −6.1% |
| Shareholder yield | 0.00% (better) | −6.1% |
| Ownership | ||
| Held by institutions | 0.66% | 9.3% |
| Held by insiders | 11.4% | 0.00% |
| Insider net buying, 12 months | −$17 | – |
| Short interest, % of float | 17.2% | 3.2% |
Go deeper
- DCOY stock overview
- DCOY income statement
- DCOY valuation and score
- NNVC stock overview
- NNVC income statement
- NNVC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.